What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

09/05/2017

HAYWARD, CA (May 08, 2017) – RefleXion Medical, a medical equipment company developing the first biology-guided radiotherapy (BgRT) system for targeted, personalized radiotherapy, announced today that industry veteran Todd Powell has been appointed President, CEO and a Board of Directors member. Powell spent the past 29 years developing innovative products while leading global organizations in cancer care. During a distinguished 11 year career at Elekta AB, a world leader in radiation oncology solutions, Powell held senior executive roles of increasing responsibility. Most recently, he served as Executive Vice President of Comprehensive Oncology Solutions where he led a business unit with more than $1B in revenue and 1,200 employees across North America, Europe and Asia.
From 1992 through 2005, Powell worked at IMPAC Medical Systems, a leader in information systems for radiation and medical oncology. In 1997 he became VP of Product Engineering & Development and was involved with the company’s successful public offering and subsequent acquisition by Elekta in 2005. Powell began his career as an Oncology Marketing and Business Specialist at Varian Medical Systems.
He completed Executive Innovation and Leadership Programs at Stanford Graduate School of Business in 2010, and earned a Bachelor of Physics and Mathematics from California State University-Chico in 1990.

“I’m excited to join the tremendous innovators at RefleXion Medical,” said Powell. “Radiation therapy is a cost-effective pillar of cancer treatment, and RefleXion is developing the most profound advance in radiotherapy I’ve seen in decades. By leveraging biological signals from tumors during treatment, this company has the potential to significantly improve cancer care for millions of patients across the world.”
“Todd has a sterling record of achievement in our industry,” said Samuel Mazin, Ph.D., Founder and Chief Technology Officer of RefleXion. “He shares our passion for dramatically transforming and improving how cancer patients are treated with radiotherapy. He also knows how to grow a successful global brand and business. We feel fortunate to have him heading our fast-growing team.”

About RefleXion Medical
RefleXion Medical is a privately held medical device company developing the first biology-guided radiotherapy (BgRT) system for cancer treatment. By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion’s patented technology causes tumors to continuously signal their location during treatment, potentially revolutionizing treatment of metastatic disease. RefleXion is backed by premier investment firms Sofinnova Partners, KCK Group, Pfizer Venture Investments, Venrock and Johnson & Johnson Innovation – JJDC, Inc. The company has also received grant funding from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program. For more information, visit www.reflexionmedical.com and follow @reflexionmed on Twitter.

05/05/2017

• Vaccine was safe and elicited a potent immune response
• Cytomegalovirus (CMV) infection is the leading cause of birth defects in the developed world, occurring in 1 – 2.5 % of all newborns and conferring risk of deafness and impaired intellectual development
Vienna, Austria, 4 May 2017 – Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today presented the un-blinded safety and immunogenicity data through month four from the Company’s phase 1 first-in-human trial of HB-101, a vaccine against human cytomegalovirus (CMV), based on Hookipa’s proprietary Vaxwave® platform. The data was presented at the CMV 2017 Conference (www.cmv2017.nl/home) in Leeuwenhorst, The Netherlands. Further follow-up safety and immunogenicity results through month 12 of the study are expected in November 2017.

Joern Aldag, Hookipa’s CEO, said; “These clinical data show that Hookipa’s Vaxwave® technology and, specifically, the bivalent CMV vaccine candidate HB-101 are safe and immunogenic. We are pleased to note that the vaccine elicited potently CMV-neutralizing antibodies and high frequencies of CMV-specific CD8+ T cells with as few as two doses of the vaccine. These results provide confidence that Hookipa can establish HB-101 as a best-in class CMV development program. Our team around Dr. Anders Lilja did an amazing job running this program and we are actively gearing up for Phase 2 efforts.”

HB-101 is a bivalent CMV vaccine candidate based on Vaxwave® vectors expressing two human CMV antigens, the tegument protein pp65 and a truncated isoform of the fusion protein gB. The safety and immunogenicity of HB-101 were evaluated in a randomized, placebo-controlled, double-blind phase I dose-escalating trial (NCT02798692). Three cohorts of 18 subjects per cohort were enrolled. In each cohort, 14 subjects received a high, medium or low dose of the vaccine, respectively, and four received placebo. Vaccine and placebo were administered on day zero, and one and three months after first injection. Safety and reactogenicity data were collected and reviewed by an independent data and safety monitoring board. Immunogenicity readouts included humoral and cellular responses against gB, cellular responses against pp65, as well as humoral and cellular responses against the vector.

Over all three dose groups, 98% of the subjects who received vaccine, and zero percent of the subjects who received placebo, showed detectable CMV-neutralizing antibody titers after three doses (93% of the subjects in the lowest dose group and 100% of the subjects in the medium and high dose groups). In the highest dose group, 100% seroconversion was already observed after the second vaccination and 79% of the subjects who received vaccine in this group, showed titers within the range of seropositive controls. Similarly, all three dose groups of the vaccine induced robust and statistically significant cellular immune responses when compared to placebo. When looking specifically at pp65-specific CD8+ T cells, a key biomarker for cellular immunity against cytomegalovirus, the medium and high dose groups induced clinically and statistically significant responses when compared to placebo.

About Hookipa Biotech
Hookipa Biotech is developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms. By end April 2017, Hookipa has raised EUR 15 million in non-dilutive funds and EUR 37 million equity investment from internationally renowned venture capital investors including Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners. Additional information on Hookipa is available at www.hookipabiotech.com.

About Vaxwave®
Hookipa´s Vaxwave® technology presents a completely new replication-defective viral vector platform designed to overcome the limitations of current technologies. Vaxwave® is based on lymphocytic choriomeningitis virus (LCMV) and in this vector the gene encoding the LCMV envelope protein, normally responsible for virus entry into target cells, has been deleted and replaced with a target gene of interest. The resulting vectors infect target cells and stimulate very potent and long-lasting immune responses, however they can no longer replicate and are therefore non-pathogenic and inherently safe.
About Cytomegalovirus
Cytomegalovirus (CMV) is a ubiquitous human pathogen that is the leading cause of congenital infection worldwide, occurring in 1 – 2.5 % of all newborns in the developed world. Newborns infected with CMV are at risk of deafness and impaired intellectual development. Cytomegalovirus is also a severe pathogen for transplant recipients causing end organ diseases. The development of CMV vaccines is a widely acknowledged public health priority.

Issued for and on behalf Hookipa Biotech AG by Instinctif Partners. For further information please contact:

At the Company
Marine Popoff
Communications Analyst
Hookipa Biotech AG
Mpopoff@Hookipabiotech.com

Media enquiries
Sue Charles/ Daniel Gooch/ Alex Bannister
Instinctif Partners
hookipa@instinctif.com
+44 (0)20 7866 7905

19/04/2017

Toulouse, FRANCE, Ann Arbor, UNITED-STATES, April 18, 2017, 8.00 AM – Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of innovative lipid metabolism therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, today announces that de Phase 1 clinical trial with CER-209, a P2Y13 receptor agonist, has been initiated.
Dr. Jean-Louis Dasseux, founder and CEO of Cerenis, declares: « According to the American Liver Foundation, NASH is one of the leading causes of cirrhosis in adults in the United-States. 25% of adults having NASH will develop a cirrhosis, and there currently are no approved therapies for these diseases. In addition, epidemiological studies demonstrate that the cardiovascular risk is increased in patients with hepatic steatosis and that the cardiovascular diseases associated are the leading causes of death in patients with liver steatosis1,2.
We believe that CER-209, new patented molecule coming from our research, has the potential to play an innovative part by both addressing hepatic steatosis and atherosclerosis. CER-209’s major asset in NASH and NAFLD treatment lies in its ability to promote HDL recognition and lipid elimination by the liver, through the activation of natural metabolic pathways mediated by the P2Y13 receptor.
The entry of CER-209 into clinical development makes part of Cerenis’ strategy which is based on a rich portfolio of several products at different development stages and operating through diversified mechanism of action, which constitutes as many growth drivers for the company”.
Incidence of NAFLD and NASH is increasing, now becoming common diseases of the liver in part related to the rise in obesity and diabetes rates. NAFLD, a precursor of NASH, is a universal disorder that is now considered as the most common liver disease in the western world, impacting 30% of the world’s population, according to a publication in the World Journal of Hepatology.
Launch of the Phase 1 clinical study with CER-209, within the framework of an IND
The launch follows the FDA IND (Investigational New Drug application) approval, granted in December 2016, to initiate the clinical development of CER-209 in healthy volunteers for the clinical investigation of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).
1 Franque S. M. et al. Journal of Hepatology, 2016, vol. 65, 425-443
2 World J Gastroenterol 2015 June 14; 21(22): 6820-6834

The objective of this randomized, double blind and placebo controlled trial, is to evaluate efficacy and tolerance and also the pharmacokinetic/pharmacodynamics following the administration of CER-209’ increasing doses in healthy volunteers.
CER-209, an agonist of the P2Y13 receptor, is well suited to the treatment of NAFLD and NASH
CER-209, a selective novel agonist of the P2Y13 receptor decreased both atherosclerosis and liver steatosis in preclinical models. CER-209 caused an increased uptake of high-density lipoprotein-cholesterol (HDL-c) in the liver that is associated with stimulation of bile acid secretion. Repeated dose administration stimulated the apoA-I synthesis and formation of small HDL particles, known to be atheroprotective. CER-209-treated plasma samples had high cholesterol efflux capacity for the mobilization of cellular cholesterol in vitro compared with the placebo group. CER-209 induced a decrease in atherosclerotic plaques in aorta and carotids as well as a remarkable decrease in steatosis in validated preclinical models.
In preclinical models, CER-209 resulted in a marked reduction in overall steatohepatitis as determined by reductions in cholesterol, triglycerides and fatty acids in the liver compared with placebo. Furthermore, CER-209 produced considerable decreases in liver enzymes (ALT and AST) in the plasma. These effects suggest the restoration of liver integrity and indicate a strong potential for CER-209 to treat liver disease such as Non-Alcoholic Steato-Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) while reducing the risks associated with cardiovascular disease.

About CER-209
CER-209 is the first drug candidate in the category of oral P2Y13 receptor agonists. The P2Y13 receptor is a member of the P2Y receptor family, a well-known receptor family including the P2Y12 receptor that is the target of successful drugs such as the anti-thrombotic agent Clopidogrel (Plavix®). CER-209 is a specific agonist of the P2Y13 receptor and does not interact with the P2Y12 receptor. In preclinical studies CER-209 promotes HDL recognition by the liver and increases Reverse Lipid Transport (RLT), thereby impacting atherosclerosis regression. Because of the favorable metabolic effects observed in the liver, CER 209 may also offer a new mechanism for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).

About Cerenis: www.cerenis.com
Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL and other therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.
Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for patients with genetic HDL deficiency, as well as drugs which increase HDL for patients with a low number of HDL particles to treat atherosclerosis and associated metabolic diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH).
Cerenis is well positioned to become one of the leaders in this innovative lipid metabolism therapeutic market, with a broad portfolio of programs in development.

Contacts:
Cerenis
Jean-Louis Dasseux
CEO
info@cerenis.com
+33 (0)5 62 24 09 49

NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.eu
+33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
cerenis@newcap.eu
+33 (0)1 44 71 94 98

11/04/2017

Collaborative team to progress novel USP30 inhibitors to develop potential therapies for Parkinson’s disease
CAMBRIDGE, UK – 11 April 2017 – On World Parkinson’s day, Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with high unmet medical need, announced that it has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF).
This research grant will support the testing of Mission Therapeutics’ potent and selective USP30-targeted inhibitors in translationally relevant stem cell-derived Parkinson’s disease models developed by Professor Richard Wade-Martins and his research group at the University of Oxford.
USP30, a mitochondrial associated DUB, has been implicated in the control of mitophagy – a process where dysfunctional mitochondria are selectively cleared from the cell. Failure of mitochondrial quality control may lead to degeneration of the highly active substantia nigra neurons in the brain, a pathological mechanism which results in Parkinson’s disease.
The inhibition of USP30 is being studied by Mission Therapeutics to see if this promotes mitophagy and thus improves cellular resilience in this and other neurodegenerative diseases. The objective of the research collaboration with Professor Richard Wade-Martins is to test Mission’s potent and selective USP30 inhibitors in a range of disease models – induced Pluripotent Stem Cells (iPSC)-derived from patients with sporadic and familial Parkinson’s disease.
Shalini Padmanabhan, PhD, Associate Director of Research Programs at MJFF:
“USP30 is one of the more promising DUBs associated with mitophagy, in terms of published data and feasibility of compound development. We hope that this collaboration between Mission Therapeutics and Oxford Parkinson’s Disease Centre will promote our understanding of the mechanisms and consequences of USP30 inhibition in Parkinson’s disease.”
Dr Michael Koslowski, Executive Vice President, Research and Development and Chief Medical Officer of Mission Therapeutics, added:
“Receiving funding from the Michael J. Fox Foundation is a great accolade, recognizing the quality of the research being done by Mission Therapeutics and Prof. Wade-Martins and his group. The collaborative study will provide key data that will guide the clinical development strategy of our USP30 inhibitor programme. We are working hard to find new ways in which to tackle this difficult disease, which is especially highlighted during this World Parkinson Awareness week, for patients and their families.”

FOR MORE INFORMATION:
Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0) 1223 497199
Instinctif Partners
Melanie Toyne-Sewell / Eileen Paul / Priya Kalia
Tel: +44 (0) 20 7457 2020
missiontherapeutics@instinctif.com
Westwicke Partners (U.S.)
Chris Brinzey
Tel: +1 339-970-2843
Chris.brinzey@westwicke.com
About Mission Therapeutics
Mission Therapeutics, an early-stage drug development company targeting the ubiquitin pathway for the treatment of cancer, neurodegenerative, and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Cancer Research UK Laboratories and the University of Cambridge’s Jackson Laboratories at the Gurdon Institute, and a leadership team that has broad international, commercial and scientific experience.
In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

About the Michael J. Fox Foundation for Parkinson’s Research
As the world’s largest nonprofit funder of Parkinson’s research, the Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers.
In addition to funding more than $700 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials.

04/04/2017

Cambridge, UK, 4 April 2017 – Crescendo Biologics Ltd (Crescendo), the developer of multi-functional Humabody® therapeutics, today announces that Dr Philip Bland-Ward has been appointed Chief Scientific Officer (CSO). The appointment will take effect in May 2017.
With over 20 years’ experience in the biopharmaceuticals industry, Phil has played a key role in the development of novel antibody therapeutics in multiple disease areas. He joins Crescendo from Kymab where he was responsible for leading its most advanced development programme. Phil previously held senior positions at Cambridge Antibody Technology and PanGenetics, and was CSO at Navion, as well as a co-founder of Nascient.
His in-depth experience with late stage, pre-clinical development programmes, including novel antibody drug candidates, complements Crescendo’s current in-house expertise and strengthens the Company’s positioning as a provider of novel immuno-oncology products with enhanced therapeutic potential.
Phil’s role as CSO will be to drive Crescendo’s immuno-oncology (IO) and Humabody® Drug Conjugate (HDC) programmes to clinical proof-of-concept.
Dr Peter Pack, CEO of Crescendo Biologics, said:
“Over the past 24 months, Crescendo has transitioned from a technology platform company to a developer of Humabody® therapeutics. We have created a rich internal pipeline of truly differentiated, multi-functional biologics with a focus on oncology. Our growing reputation is also leading to external collaborations and licensing deals with big pharma, such the recent deal signed with Takeda.
“Our aim now is to advance our programmes rapidly to the next stage of clinical development. Phil’s appointment as CSO, coupled with his experience and standing in the field of biologics development, will be key to achieving this.”
Dr Philip Bland-Ward, the new CSO, added:
“The IO field has been a key focus for biotech companies in the last few years and it’s an area where Crescendo’s Humabody® platform is ideally positioned. The Company has produced a pipeline of multi-functional biological candidates with exciting new modes-of-action and huge therapeutic potential. I look forward to working with the team at Crescendo to advance the development of Humabody® therapeutics in oncology.”

Background on Dr Philip Bland-Ward
Phil began his career working on pain and migraine research at the Glaxo Institute of Applied Pharmacology and then at GlaxoWellcome. He joined Cambridge Antibody Technology (CAT) to lead antibody projects in neuroscience, metabolic diseases, and ophthalmology. He was Director of Oncology Biology at CAT before moving to PanGenetics to successfully lead the development of their antibody assets (pain, auto-immune disease), underpinning progression to Phase I clinical studies.
Subsequently Phil took roles as CSO of Navion (oncology) and SweetSpot Therapeutics, and co-founded Nascient (inflammatory disease) – all small companies focused on discovery and development of antibody therapeutics.
Prior to joining Crescendo, Phil was a VP at Kymab with particular responsibility for the scientific leadership of their most advanced development programme.
Phil holds a BPharm degree in pharmacy and a PhD in pharmacology, both from King’s College London.

For more information, please contact: Crescendo Biologics Dr Peter Pack, CEO Tel: 44 (0)1223 497140 info@crescendobiologics.com Instinctif Partners Dr Christelle Kerouedan / Melanie Toyne-Sewell Tel: 44 (0)20 7457 2020 crescendo@instinctif.com ICR Inc. Stephanie Carrington/James Heins Tel: 646-277-1282/203-682-8251 crescendo@icrinc.com

Notes to Editors:
About Crescendo Biologics Ltd
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated mono- and multi-functional Humabody® therapeutics in oncology. The Company’s Humabody® therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH) with superior biophysical properties and developability.
Crescendo is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships in both multi-specific immuno-oncology modulators and Humabody® Drug Conjugates (HDCs), the next generation of ADCs.
Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.
For more information, please visit the website: www.crescendobiologics.com .

About Humabody® Therapeutics
Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human VH domain building blocks (Humabody® VH) isolated from heavy chain-only antibodies produced using Crescendo’s proprietary transgenic mouse.
Compared with monoclonal antibodies, Humabodies offer a unique combination of potential benefits resulting from their small size, cost-effective production and robust biophysical properties. These attributes allow Crescendo to optimally configure an almost limitless range of multifunctional Humabody® formats in a rapid timeframe.
Crescendo is developing a pipeline of novel, Humabody®-based therapeutics in oncology. Its next-generation mono- and multi-specific Humabody® immune-oncology modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response, as well as enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment. Its Humabody® Drug Conjugates (HDCs) deliver a superior therapeutic index to standard ADCs.
For more information, please visit the website: www.crescendobiologics.com.

28/03/2017

• Antoine Papiernik succeeds Denis Lucquin, who was Sofinnova Partners’ Chairman for ten years, and remains a Managing Partner of the venture capital firm.
• Sofinnova Partners boosts its growth strategy to further strengthen its leadership in Life Sciences investments.
Paris, France – March 28th. 2017 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Antoine Papiernik as Chairman. Papiernik succeeds Denis Lucquin who remains a Managing Partner. The appointment starts a new chapter in Sofinnova Partners’ growth strategy.

Antoine Papiernik joined Sofinnova Partners in 1997 and has a proven track record investing in companies that have gone on to be publicly listed on international exchanges or been acquired by leading players in the sector. He has been the lead investor in public companies like Actelion, ProQR, NovusPharma, Movetis, Mainstay, Pixium Vision and Stentys which have listed on a wide range of exchanges including the Zürich stock exchange, NASDAQ, Milan’s Nuovo Mercato, Euronext Brussels, the Dublin stock exchange and Euronext Paris. He was also the lead investor at inception of CoreValve (sold to Medtronic), Fovea (sold to Sanofi) and Ethical Oncology Science (sold to Clovis Oncology). He is a currently the lead investor and sits on the Board of Gecko Biomedical, MD Start, Shockwave Medical, Rgenix, Corwave, and Reflexion Medical. Antoine has an MBA from the Wharton School of Business, University of Pennsylvania. In 2012 and 2011, he was selected by Forbes for its “Midas List” of the world’s top 100 venture capital investors.

Denis Lucquin said: “Passing on the responsibilities of Chairman in a partnership is a crucial event, and I have full confidence in Antoine taking on this role. Sofinnova Partners is entering a new phase, and the timing is perfect for this change. Antoine stands out for his investment track record and has become a key personality in the world of venture capital, in Europe as well as in the United States. He is also a talented team leader. Antoine has exactly what it takes to drive Sofinnova Partner’s future development.”

Antoine Papiernik added: “It is a great honor to succeed Denis. In the past ten years, under his chairmanship, we successfully completed the firm’s strategic refocus on its core business: Life Sciences investments. Thanks to our investors’ confidence, we significantly grew our assets under management, which today total more than 1.6 billion euros. Moving forward our vision for Sofinnova Partners entails growing our activity and further strengthening our leading position in Life Sciences investments.”

Sofinnova Partners’ recent achievements include numerous successes: exits for a total enterprise value worth more than 4 billion euros over the past four years, thanks to 10 IPOs and several M&As, such as Delinia which was sold to Celgene in January 2017 for a total enterprise value of $775 million (€725 million).

In the coming years, Sofinnova Partners will further expand its coverage of the Life Sciences sector, with dedicated teams and investment vehicles. Following the closing in December 2015 of its Capital VIII Fund (€300 million) dedicated to early stage healthcare investments, Sofinnova Partners has recently achieved a first close at €106 million of its IB I Fund, entirely dedicated to industrial biotech investments. Other healthcare-related innovation funds are currently under review. With 29 people and 10 different nationalities, Sofinnova Partners’ team is remarkably international. As its growth strategy develops, the firm plans on expanding its team with a significant number of new hires in the next two years.

Press contact for SOFINNOVA PARTNERS
Anne REIN
Tel: +33 6 03 35 92 05
@: anne.rein@strategiesimage.com

27/03/2017

LEIDEN, the Netherlands, March 27, 2017 – ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in drug development including leadership roles in translational medicine, rare disease drug development, and RNA therapeutics. Dr. Rodman’s experience includes a leadership role in developing two approved medicines for cystic fibrosis (CF) at Vertex Pharmaceuticals, as vice president and head of respiratory drug development. He was also the head of translational medicine at Novartis Institute for Biomedical Research. More recently, he was the Chief Medical Officer at MiRagen and Nivalis. Expansion of the ProQR management team will allow the company to unlock the potential of RNA therapeutics as well as expand business capabilities needed to advance the development of our product candidates that now include three programs: QR-010 for CF, QR-110 for Leber’s congenital amaurosis Type 10, and QR-313 for dystrophic epidermolysis bullosa.

“At ProQR we are just beginning to capitalize on the power of RNA based therapeutics. We believe RNA therapeutics offers a powerful therapeutic approach to severe genetic disease. We believe the RNA approach has advantages over other approaches, and we are excited to fully explore the possibilities for patients. By adding Dave to our leadership, we will be able to strengthen our portfolio and strategically build our pipeline of RNA approaches to treating disease.” said Noreen R. Henig, MD, Chief Medical Officer.

“There are very few opportunities like ProQR where a great team, cutting edge science and the passion for patients come together” said David M. Rodman, MD, “In joining ProQR I look forward to continue to make an effort for CF patients, but also on making a big impact for patients suffering from other rare diseases.”

“In the ProQR tradition of only working with the best of the best, I’m very pleased that Dave is joining our team” said Daniel de Boer, Chief Executive Officer of ProQR. “Between Gerard (Platenburg, Chief Innovation Officer), Dave and Noreen we cover all key capabilities from invention to translation to late stage development.”

About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*

About Cystic Fibrosis
CF is the most common fatal inherited disease in the Western world and affects an estimated 65,000 patients worldwide. In people with CF, a defective CFTR gene causes a thick, buildup of mucus in the lungs, pancreas and other organs. In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure. There is no cure for CF. Disease manifestations lead to a shortened life expectancy with a median age of death of 30 years or less. Although over 1,900 CF-causing gene mutations have been identified, approximately 85% of all CF patients are affected by the F508del mutation. Among all CF patients, approximately 45% are homozygous for the F508del mutation.

About Leber’s Congenital Amaurosis Type 10
Leber’s congenital amaurosis is the most common genetic cause of blindness in children and consists of a group of diseases of which LCA Type 10 (LCA 10) is one of the more severe forms. LCA 10 leads to progressive loss of vision causing most patients to lose their sight in the first few years of life. To date, there are no treatments approved or product candidates in clinical development that treat the underlying cause of this specific subtype of the disease. LCA 10 is caused by mutations in the CEP290 gene of which the p.Cys998X mutation is most common. Although prevalence rates vary, we believe approximately 2,000 people in the Western world have LCA 10 because of this mutation.

About Dystrophic Epidermolysis Bullosa
Dystrophic epidermolysis bullosa (DEB) is a rare genetic disorder of the skin and mucosal membranes and is characterized by fragile skin, severe blistering and poorly healing wounds that result from minimal pressure. Some forms of DEB are painful and debilitating and are associated with very low quality of life and a limited life expectancy. The disease is caused by mutations in the COL7A1 gene that lead to a weak connection between the dermis (inner layer) and the epidermis (outer layer) in the skin. Approximately 2,000 patients have DEB because of mutations in exon 73 of the COL7A1 gene. There is currently no treatment available.

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding QR-010, QR-110 and QR-313, statements regarding our ongoing and planned discovery and development of existing and future product candidates, statements regarding our RNA approach to treating diseases and statements regarding the appointment of David M. Rodman to our management team. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
ir@proqr.com

14/03/2017

 

  • Actively backed by international investors, the IPO was multiple times oversubscribed. 
  • Avantium’s market capitalisation reaches €277 M after capital increase of €103 M 
  • Avantium’s IPO is a strong endorsement of Sofinnova Partners strategy in Industrial Biotech and Renewable Chemistry

 Paris, France – March 14th. 2017. Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, today announced the successful initial public offering of Avantium which raised €103 M on Euronext Amsterdam and Euronext Bruxelles. Sofinnova Capital VI remains the main shareholder after the IPO. The initial public offering was multiple times oversubscribed.

Based in Amsterdam, Avantium is a pioneer company specialized in renewable and sustainable chemicals which develops efficient processes and sustainable products made from biobased materials. Avantium offers a breeding ground for revolutionary renewable chemistry solutions. From invention to commercially viable production processes. One of Avantium’s many success stories is the YXY technology to produce PEF: a completely new, high-quality plastic made from plant-based industrial sugars. PEF is 100% recyclable. It offers a cost-effective solution for applications ranging from bottles to packaging film and fibres, positioning it to become the next generation packaging material.

Funds raised will be used to further commercialise Avantium’s inventions into viable production processes. This will start with the commercialisation of the YXY technology, in joint venture with BASF, by building the first commercial scale reference plant for FDCA. This is an important step in Avantium’s strategic development to become a world leader in renewable chemistry. Avantium has a proven capacity to attract renowned global partners throughout the entire value chain, such as The Coca-Cola Company, Danone, Toyobo, ALPLA and Mitsui. Besides the YXY technology, the company is working on other projects which for some have reached or entering pilot plant stage.

Denis Lucquin, Managing Partner at Sofinnova Partners and Avantium Board member since 2011 declares: « Avantium has completed one of the most successful IPOs in this emerging and promising renewable chemistry sector. This success comes just a few weeks after Sofinnova Partners announced the first closing of its Sofinnova IB I Fund entirely dedicated to renewable chemistry, and fully validates our vision and strategy. As lead investor, and still main shareholder after the IPO, we are extremely pleased with this listing. It confirms investors’ confidence in the team’s talent and ability to transform a visionary project into a performing global company ».

Avantium issued 9,401,793 shares allowing a capital increase of €103 M. On this basis at €11 per share, Avantium’s market capitalization reaches €277 M. Trading will begin on March 15th 2017 on Euronext Amsterdam and Euronext Bruxelles under the symbol AVTX. Please refer to the company’s press release (www.avantium.com) for additional information on the listing.

 

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and for more than 40 years has backed nearly 500 companies creating market leaders around the globe. Today, Sofinnova Partners has over 1.3 billion of funds under management. For more information, please visit: www.sofinnova.fr

About Avantium
Avantium is a leading chemical technology company and a forerunner in renewable chemistry. Together with its partners around the world, Avantium develops efficient processes and sustainable products made from biobased materials. Avantium offers a breeding ground for revolutionary renewable chemistry solutions. From invention to commercially viable production processes. One of Avantium’s many success stories is the YXY technology to produce PEF: a completely new, high-quality plastic made from plant-based industrial sugars. PEF is 100% recyclable. It offers a cost-effective solution for applications ranging from bottles to packaging film and fibres, positioning it to become the next generation packaging material.

13/03/2017

– IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer as part of assisted reproductive technology (ART) –
Geneva, Switzerland – 07 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced initiation of its Phase 3 clinical program evaluating the efficacy and safety of nolasiban to improve pregnancy and live birth rates in women undergoing ART. The study is being conducted in 10 European countries.
Nolasiban is an oral oxytocin receptor antagonist that potentially improves pregnancy and live birth rates following embryo transfer (ET). In a completed Phase 2 study, 43 percent of patients treated with 900 mg of nolasiban before ET achieved a live birth compared to 29 percent of patients who received placebo.
“Based on our promising Phase 2 data, we are starting a large confirmatory study to assess the efficacy and safety of a single, oral administration of 900 mg of nolasiban before embryo transfer on either Day 3 or Day 5 following egg retrieval,” said Ernest Loumaye, MD, PhD, OB&GYN, CEO and Co-Founder of ObsEva. “We believe that should this trial confirm an absolute increase in live birth rates of about 10 percent, or greater, it would represent a major advance for the patients undergoing these demanding procedures to fulfill their desire to have a child.”
The IMPLANT2 clinical trial is being conducted at approximately 50 fertility clinics across Europe, and is expected to enroll about 760 women who are undergoing assisted reproduction by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) for low fertility. Following ovarian stimulation, egg retrieval and fertilization, eligible women will be randomized to receive either a single oral dose of 900 mg nolasiban or placebo a few hours before Day 3 or Day 5 ET. Treatment allocation will be blinded. A pregnancy test will be done after two weeks and pregnancies confirmed by ultrasound at 6 and 10 weeks. The primary outcome is ongoing pregnancy at 10 weeks after ET. Women with confirmed pregnancies will be monitored until the birth of their babies. Babies will be monitored for one to six months after birth.

About Assisted Reproductive Technology
Infertility affects about 10 percent of reproductive-aged couples, with approximately 1.6 million ART treatments (including IVF and ICSI) performed worldwide each year.
While the success of ART depends on multiple factors such as embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation. Uterine contractions at the time of ET, as well as suboptimal thickness of the uterine wall and blood flow to the uterus, may impair the implantation of the embryo.

About Nolasiban
Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation, all of which may increase the chance of successful pregnancy and live-birth among
patients undergoing ART. ObsEva licensed nolasiban from Merck-Serono in 2013 and retains worldwide commercial rights.

About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol “OBSV”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the trial design of OBE001, including total enrollment, as well as the potential benefits of OBE001. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Registration Statement on Form F-1, as amended, declared effective by the Securities and Exchange Commission (SEC) on January 25, 2017, and other filings ObsEva makes with the SEC from time to time. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526
Company Contact:
Delphine Renaud
ObsEva, CEO Office
delphine.renaud@obseva.ch
+41 22 552 1550

08/03/2017

– Led by top-tier life science venture capitalists Gimv and Sofinnova Partners
– Funds to execute pivotal program in Bronchiolitis Obliterans Syndrome

Munich, Antwerp, Paris, Utrecht, March 8th, 2017 — Breath Therapeutics Holding BV (Breath Therapeutics), a company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, today announced the closing of a EUR 43.5 million Series A financing. Gimv and Sofinnova Partners co-led the round and were joined by Gilde Healthcare. PARI Pharma supports the program. With the proceeds from the financing, Breath Therapeutics plans to conduct phase 3 trials in Europe and the US, respectively, submit for marketing approval, and prepare for commercialization.
Breath Therapeutics’ lead program develops a first-in-class inhalation therapy for treatment of Bronchiolitis Obliterans Syndrome (BOS). BOS is a lethal orphan respiratory disease, mainly affecting lung transplant patients. It is commonly understood as chronic graft rejection and is the main reason for the poor 5-year survival rates after lung transplantation.
Based on work by PARI Pharma and lung transplantation expert Aldo Iacono, MD, University of Maryland, USA, Breath Therapeutics develops a proprietary drug/device combination. This involves a formulation of liposomal cyclosporine A for inhalation and an optimized high performance eFlow® technology nebulizer enabling remote adherence monitoring. This approach is expected to ensure a safe, well tolerated and targeted delivery of immunosuppressive medication directly into the lungs along with a time saving treatment regime.
Breath Therapeutics is a spin-off of PARI Pharma, Starnberg, Germany. The company’s founding and management team includes highly experienced executives and internationally renowned experts in drug aerosol and immunosuppression therapy: Dr. Jens Stegemann (CEO), Anne Burger (CFO), Dr. Gerhard Boerner (CSO) and Dr. Oliver Denk (COO). Graziano Seghezzi, partner at Sofinnova Partners, Dr. Karl Nägler, partner at Gimv, and Arthur Franken, partner at Gilde Healthcare, will join the board of directors.
Dr. Jens Stegemann, CEO of Breath Therapeutics, said: “BOS is one of the most devastating lung diseases and still today, no effective therapy is available. Our strategy is to deposit high concentrations of an immunosuppressive agent directly into the small airways of the lung. With this top-tier group of investors and the best international lung transplantation centres supporting us, we now are in an excellent position to achieve ground-breaking improvements in the combat of BOS.”
Graziano Seghezzi, partner at Sofinnova Partners, added: “We are thrilled to be involved with Breath Therapeutics. We were really impressed by its highly talented and entrepreneur-oriented team, as well as by the potential of its market breaking technology. At Sofinnova Partners we have a strong expertise in turning corporate spin-offs into successful companies, and are happy to share our experience and resources with the team to back Breath Therapeutics’ growth.”
Dr. Karl Nägler, partner at Gimv, commented: “It is a great opportunity to invest in a company focusing on a life-threatening orphan disease with high unmet medical need. We were attracted by the strong expertise of the founding team and by the very promising late-stage clinical data. Furthermore, the BOS market will allow for a focused and highly profitable commercialisation strategy.”
Arthur Franken, partner at Gilde Healthcare, said: “This talented team has designed a unique drug/device combination which together with digital adherence monitoring has great potential to improve quality of care for patients suffering from chronic lung graft rejection. Gilde will actively support Breath Therapeutics and its team in its growth strategy of developing and commercializing inhaled drug therapies for severe respiratory disease.”
Dr. Martin Knoch, President of PARI Pharma, said: “The team at Breath Therapeutics has the expertise and focus to bring the first lung-targeted BOS therapy through clinical development and hopefully onto the market. For PARI Pharma it is highly rewarding to see a project that we started advancing into late-stage clinical development and providing BOS patients new hope.”

About Breath Therapeutics
Breath Therapeutics is specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases. For its clinical development, the company is using proprietary drug formulations optimized for inhaled administration with exclusively licenced, high performance nebulizers. Breath Therapeutics is focussing on integrated therapy solutions in the interaction between diagnostic, therapy and eHealth therapy control. The clinical development program is addressing the treatment of Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. PARI Pharma, a leading nebulizer company, is strategic partner and technology licensee for the BOS development program. Breath Therapeutics is based in Munich and Frankfurt, Germany.
For more information, please visit: www.breath-therapeutics.com.

About Gimv
Gimv is a European investment company with over three decades’ experience in private equity and venture capital. The company is listed on Euronext Brussels. Gimv currently manages around 1.8 billion EUR (including co-investment partnerships) of investments in about 50 portfolio companies. As a recognized market leader in selected investment platforms, Gimv identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders. Gimv’s four investment platforms are: Connected Consumer, Health & Care, Smart Industries and Sustainable Cities. Each of these platforms works with a skilled and dedicated team across Gimv’s home markets of the Benelux, France and Germany and can count on an extended international network of experts.
For more information, please visit: www.gimv.com.
About Sofinnova Partners
Sofinnova Partners is an independent venture capital firm based in Paris, France. For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside key entrepreneurs in the Life Sciences industry around the globe. With over € 1.6 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit.
For more information, please visit: www.sofinnova.fr.

About Gilde Healthcare
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a European specialist investment firm focused on private healthcare companies. It has over € 800 million ($ 900 million) under management and is actively looking to lead new investments in therapeutics, medical devices, digital health and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to € 30 million in a single portfolio company. Gilde is currently investing out of GHC IV which is financed, in part, by the European Recovery Program-European Investment Fund Facility.
For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

About PARI Pharma GmbH
PARI Pharma recognizes that the future of aerosol therapies is the combined optimization of the drug formulation and the delivery device – a core competence of PARI Pharma in the global network of PARI Worldwide companies. The focus of PARI Pharma is the optimization of advanced aerosol delivery platforms, based on the eFlow Technology, with new liquid medications. The goal is to enable short and effective treatments that lead to increased patient adherence, disease control, and improved quality of life for patients. By optimizing drug and device under one roof, PARI Pharma increases the speed of development for pharmaceutical partners.
For more information, please visit www.paripharma.com.

Contact:
MC Services AG
Raimund Gabriel, Managing Partner.
Tel. +49 89 210 228–60
Email: breath-therapeutics@mc-services.eu